Molecule Details
| InChIKey | NJIAKNWTIVDSDA-FQEVSTJZSA-N |
|---|---|
| Canonical SMILES | CS(=O)(=O)N1CCC(c2ccc(-c3cc4nccnc4c(NC[C@@H]4CNCCO4)n3)cc2)CC1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.93 |
| Source | ChEMBL |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB17557 |
|---|---|
| Drug Name | Sovleplenib |
| CAS Number | 1415792-84-5 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia). |
Cross-references: ChemSpider: 115010433 ZINC: ZINC000143715528